NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Phase 1

Recruiting

Conditions: Metastatic Microsatellite Stable Colorectal Carcinoma
Refractory Microsatellite Stable Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8

Interventions: Drug: Abemaciclib
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Fluorouracil
Procedure: Radiologic Imaging Procedure

First Posted Date: 2024-10-23

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT06654037

Locations: 🇺🇸
University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 2 locations

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Phase 2

Not yet recruiting

Conditions: Mesothelioma
Malignant Mesothelioma (MM)
Early-stage Mesothelioma
Subclinical Mesothelioma
BRCA1-Associated Protein-1 (BAP1) Mutations
Early-stage BAP1-associated Malignancies

Interventions: Drug: alrizomadlin

First Posted Date: 2024-10-23

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT06654050

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Phase 2

Not yet recruiting

Conditions: Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Ibrutinib
Drug: Lenalidomide
Procedure: Magnetic Resonance Imaging
Biological: Obinutuzumab
Procedure: Positron Emission Tomography
Drug: Prednisone
Drug: Venetoclax

First Posted Date: 2024-10-21

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT06649812

Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome

Phase 2

Recruiting

Conditions: Cushing Syndrome

Interventions: Drug: Desmopressin
Drug: Dexamethasone

First Posted Date: 2024-10-10

Last Posted Date: 2025-05-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 140

Registration Number: NCT06635629

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)

Not Applicable

Recruiting

Conditions: Cervical Carcinoma
Human Papillomavirus Infection

Interventions: Procedure: Biospecimen Collection
Procedure: Cervical Biopsy
Procedure: Colposcopy
Other: Electronic Health Record Review
Procedure: Endocervical Curettage
Procedure: Excision
Procedure: HPV Self-Collection
Procedure: Human Papillomavirus Test
Other: Questionnaire Administration
Other: Survey Administration

First Posted Date: 2024-09-25

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT06611553

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

and more 22 locations

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

Not Applicable

Recruiting

Conditions: Cervical Carcinoma
Human Papillomavirus Infection

Interventions: Procedure: Biospecimen Collection
Procedure: Cervical Biopsy
Procedure: Colposcopy
Other: Electronic Health Record Review
Procedure: Endocervical Curettage
Procedure: Excision
Procedure: HPV Self-Collection
Procedure: Human Papillomavirus Test
Other: Questionnaire Administration

First Posted Date: 2024-09-25

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT06611540

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

and more 22 locations

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

Phase 1

Recruiting

Conditions: Metastatic Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Biological: Pidnarulex

First Posted Date: 2024-09-23

Last Posted Date: 2025-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT06606990

Locations: 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1

Suspended

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Invasive Breast Carcinoma
Locally Advanced HER2-Negative Breast Carcinoma
Locally Advanced Hormone Receptor-Positive Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
Metastatic HER2-Negative Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Unresectable HER2-Negative Breast Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Eribulin Mesylate
Procedure: Magnetic Resonance Imaging
Drug: Tolinapant
Procedure: X-Ray Imaging

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT06590558

Locations: 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
Ohio State University Comprehensive Cancer Center LAO, Columbus, Ohio, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Phase 2

Not yet recruiting

Conditions: Microsatellite Stable Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Colorectal Cancer

Interventions: Biological: Tiragolumab
Biological: Atezolizumab
Radiation: Stereotactic Body Radiation Therapy (SBRT)

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT06603818

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase 3

Recruiting

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Laryngeal Squamous Cell Carcinoma
Metastatic Oropharyngeal Squamous Cell Carcinoma
Refractory Hypopharyngeal Squamous Cell Carcinoma
Refractory Laryngeal Squamous Cell Carcinoma
Metastatic Hypopharyngeal Squamous Cell Carcinoma
Refractory Head and Neck Squamous Cell Carcinoma
Metastatic Oral Cavity Squamous Cell Carcinoma
Recurrent Neck Squamous Cell Carcinoma of Unknown Primary
Recurrent Oral Cavity Squamous Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Biological: Cetuximab
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Procedure: Positron Emission Tomography

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 158

Registration Number: NCT06589804

Locations: 🇺🇸
Fremont - Rideout Cancer Center, Marysville, California, United States
🇺🇸
Lutheran Hospital - Cancer Centers of Colorado, Golden, Colorado, United States
🇺🇸
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States

and more 82 locations

Home Terms & Conditions Privacy Policy